[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE395904T1 - Liposome - Google Patents

Liposome

Info

Publication number
ATE395904T1
ATE395904T1 AT02016936T AT02016936T ATE395904T1 AT E395904 T1 ATE395904 T1 AT E395904T1 AT 02016936 T AT02016936 T AT 02016936T AT 02016936 T AT02016936 T AT 02016936T AT E395904 T1 ATE395904 T1 AT E395904T1
Authority
AT
Austria
Prior art keywords
liposomes
polynucleotide
cationic
dotap
eliciting
Prior art date
Application number
AT02016936T
Other languages
English (en)
Inventor
Gregory Gregoriadis
Original Assignee
Lipoxen Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9619172.1A external-priority patent/GB9619172D0/en
Priority claimed from GBGB9625917.1A external-priority patent/GB9625917D0/en
Priority claimed from GBGB9713994.3A external-priority patent/GB9713994D0/en
Application filed by Lipoxen Technologies Ltd filed Critical Lipoxen Technologies Ltd
Application granted granted Critical
Publication of ATE395904T1 publication Critical patent/ATE395904T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/803—Containing biological material in its interior
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/917—Vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
AT02016936T 1996-09-13 1997-09-15 Liposome ATE395904T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9619172.1A GB9619172D0 (en) 1996-09-13 1996-09-13 Liposomes
GBGB9625917.1A GB9625917D0 (en) 1996-12-13 1996-12-13 Liposomes
GBGB9713994.3A GB9713994D0 (en) 1997-07-01 1997-07-01 Liposomes

Publications (1)

Publication Number Publication Date
ATE395904T1 true ATE395904T1 (de) 2008-06-15

Family

ID=27268476

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02016936T ATE395904T1 (de) 1996-09-13 1997-09-15 Liposome
AT97940250T ATE228824T1 (de) 1996-09-13 1997-09-15 Liposomenzusammensetzung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97940250T ATE228824T1 (de) 1996-09-13 1997-09-15 Liposomenzusammensetzung

Country Status (11)

Country Link
US (1) US7790696B2 (de)
EP (2) EP0938298B1 (de)
JP (1) JP2001502299A (de)
KR (1) KR100507660B1 (de)
CN (1) CN1138533C (de)
AT (2) ATE395904T1 (de)
AU (1) AU728581B2 (de)
CA (1) CA2271388C (de)
DE (2) DE69738719D1 (de)
ES (2) ES2187812T3 (de)
WO (1) WO1998010748A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1146907A2 (de) * 1999-02-05 2001-10-24 Genzyme Corporation Anwendung von kationische lipiden zu induzieren von anti-tumorimmunität
CN1196474C (zh) * 1999-10-01 2005-04-13 利普森技术有限公司 脂质体包封的dna口服疫苗
AU1871501A (en) 1999-12-13 2001-06-18 Lipoxen Limited Liposomes
US6372250B1 (en) * 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
DE10109897A1 (de) * 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
DE60310562T2 (de) 2002-07-05 2007-10-11 Lipoxen Technologies Ltd. Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
JP4546115B2 (ja) * 2004-03-05 2010-09-15 三菱化学メディエンス株式会社 細胞中ａｔｐの定量法
DE102004057303A1 (de) * 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
CN100400667C (zh) * 2006-06-27 2008-07-09 浙江大学 脂质体包裹弓形虫pGRA4真核表达质粒的方法及用途
CA2687208C (en) 2006-12-22 2017-02-14 Soluciones Biotecnologicas Innovacion Ltda Process and formulation for immunizing fish in aquaculture systems
EP2184054A1 (de) 2008-11-08 2010-05-12 Lipoxen Technologies Limited SiRNA-Abgabe
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
ES2573427T3 (es) * 2009-07-06 2016-06-07 Variation Biotechnologies Inc. Procedimientos para preparar vesículas y formulaciones producidas a partir de las mismas
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
HUE038039T2 (hu) 2009-12-01 2018-09-28 Translate Bio Inc mRNS bejuttatása fehérjék és enzimek kiegészítésére humán genetikai betegségekben
CN102884041B (zh) * 2010-04-28 2015-04-15 协和发酵麒麟株式会社 阳离子性脂质
PL2591114T3 (pl) 2010-07-06 2017-08-31 Glaxosmithkline Biologicals Sa Immunizacja dużych ssaków małymi dawkami rna
MX343410B (es) 2010-07-06 2016-11-04 Novartis Ag * Emulsiones cationicas de agua en aceite.
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
PL2590626T3 (pl) 2010-07-06 2016-04-29 Glaxosmithkline Biologicals Sa Liposomy z lipidami o korzystnej wartości pka do dostarczania rna
MX342138B (es) 2010-07-06 2016-09-14 Variation Biotechnologies Inc Composiciones y metodos para el tratamiento de influenza.
DK2590676T3 (en) 2010-07-06 2016-10-24 Glaxosmithkline Biologicals Sa Virionlignende feed particles to self-replicating RNA molecules
EP3981427B9 (de) 2010-08-31 2022-07-27 GlaxoSmithKline Biologicals S.A. Pegylierte liposomen zur auslieferung von immunogen-kodierender rns
MX363307B (es) 2010-10-11 2019-03-20 Novartis Ag Star Plataformas para suministro de antigenos.
BR112013017939B1 (pt) 2011-01-13 2022-11-16 Variation Biotechnologies Inc Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
RU2491062C2 (ru) * 2011-03-16 2013-08-27 Общество С Ограниченной Ответственностью "Биотехнологии Пущино" Композиции протекторов острых и хронических печеночных энцелопатий и способ лечения острых и хронических печеночных энцелопатий
US10738355B2 (en) 2011-05-24 2020-08-11 Tron-Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Ggmbh Individualized vaccines for cancer
KR20240135871A (ko) 2011-06-08 2024-09-12 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
EP3332802A1 (de) 2011-07-06 2018-06-13 GlaxoSmithKline Biologicals SA Immunogene kombinationszusammensetzungen und ihre verwendung
MX350258B (es) 2011-07-06 2017-08-31 Novartis Ag Emulsiones cationicas de aceite en agua.
CA2840913C (en) 2011-07-06 2020-01-21 Novartis Ag Oil-in-water emulsions that contain nucleic acids
WO2013104995A2 (en) 2012-01-12 2013-07-18 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
EP4008354A1 (de) 2012-01-27 2022-06-08 Variation Biotechnologies Inc. Verfahren und zusammensetzungen für therapeutika
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2013185067A1 (en) 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
EP3884949A1 (de) * 2012-06-08 2021-09-29 Translate Bio, Inc. Pulmonale verabreichung von mrns an nicht pulmonale zielzellen
WO2014082729A1 (en) 2012-11-28 2014-06-05 Biontech Ag Individualized vaccines for cancer
IL305374A (en) 2013-03-14 2023-10-01 Ethris Gmbh CFTR mRNA Assemblies and Related Methods and Uses
AU2014236396A1 (en) 2013-03-14 2015-08-13 Shire Human Genetic Therapies, Inc. Methods for purification of messenger RNA
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
ES2707966T3 (es) 2013-10-22 2019-04-08 Translate Bio Inc Terapia de ARNm para la deficiencia en síntesis de argininosuccinato
CN105658242A (zh) 2013-10-22 2016-06-08 夏尔人类遗传性治疗公司 用于苯丙酮尿症的mrna疗法
RU2016130595A (ru) * 2013-12-27 2018-02-01 Телореджен, Инк. Композиции и способы, обеспечивающие активную теломеразу в клетках in vivo
US12048765B2 (en) * 2014-01-17 2024-07-30 Fundacio Institut D'investigació En Ciències De La Slut Germans Triast Pujol Liposome-based immunotherapy
KR102470198B1 (ko) 2014-04-25 2022-11-22 샤이어 휴먼 지네틱 테라피즈 인크. 메신저 rna 의 정제 방법
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
AU2018224326B2 (en) 2017-02-27 2024-01-04 Translate Bio, Inc. Novel codon-optimized CFTR mRNA
EP3624824B1 (de) 2017-05-16 2024-07-10 Translate Bio, Inc. Codonoptimierter mrna, die cftr codiert, zur verwendung in der behandlung von zystischer fibrose
WO2020041793A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna
EP3892260A1 (de) * 2020-04-10 2021-10-13 Bayer Animal Health GmbH Immunstimulierende zusammensetzungen auf der basis von liposomen mit zwitterinischen und kationischen lipiden
AU2022245985A1 (en) 2021-03-22 2023-09-21 Illumina Cambridge Limited Methods for improving nucleic acid cluster clonality

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515736A (en) 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
DE3582905D1 (de) 1984-08-10 1991-06-27 Syntex Inc Stabile liposome mit wasserloeslichen arzneimitteln.
JPH0662517B2 (ja) 1985-01-07 1994-08-17 シンテツクス（ユー・エス・エイ）インコーポレイテツド 置換アルキルートリ置換アンモニウム界面活性剤
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5545412A (en) 1985-01-07 1996-08-13 Syntex (U.S.A.) Inc. N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4885172A (en) 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
JP2627899B2 (ja) * 1987-08-19 1997-07-09 株式会社 ビタミン研究所 遺伝子封入リポソームの製法
US4882172A (en) * 1988-04-08 1989-11-21 Nabisco Brands, Inc. System for processing chewing gum
JP2923296B2 (ja) * 1988-11-14 1999-07-26 株式会社ビタミン研究所 細胞への遺伝子導入法
ATE165516T1 (de) 1989-03-21 1998-05-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) * 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
JP2958076B2 (ja) * 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
CA2128616A1 (en) 1992-01-23 1993-08-05 Gary H. Rhodes Ex vivo gene transfer
US6113946A (en) 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
DE69418334T2 (de) * 1993-08-06 2000-01-27 Opperbas Holding B.V., Amsterdam Verfahren zur hohen beladung von vesikeln mit biopolymeren substanzen
AU683957B2 (en) * 1993-11-05 1997-11-27 Amgen, Inc. Liposome preparation and material encapsulation method
JP3002702B2 (ja) * 1993-11-16 2000-01-24 スカイファーム インコーポレーテッド 活性物質の制御放出を有する小胞
IL112820A0 (en) * 1994-03-07 1995-05-26 Merck & Co Inc Coordinate in vivo gene expression
US5830430A (en) * 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
ES2231819T3 (es) * 1995-06-07 2005-05-16 Inex Pharmaceuticals Corp Particulas de lipido-acido nucleico preparadas a traves de un intermedio complejo de lipido-acido nucleico hidrofobo y uso para transferir genes.
US5830878A (en) 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting
US5753235A (en) 1996-02-15 1998-05-19 Heska Corporation Recombinant canine herpesviruses
US7384923B2 (en) * 1999-05-14 2008-06-10 Lipoxen Technologies Limited Liposomes

Also Published As

Publication number Publication date
EP1254657A3 (de) 2003-03-05
ES2305157T3 (es) 2008-11-01
CN1237102A (zh) 1999-12-01
US7790696B2 (en) 2010-09-07
CA2271388A1 (en) 1998-03-19
WO1998010748A1 (en) 1998-03-19
DE69717661D1 (de) 2003-01-16
KR20000036088A (ko) 2000-06-26
KR100507660B1 (ko) 2005-08-10
US20080286353A1 (en) 2008-11-20
ES2187812T3 (es) 2003-06-16
EP1254657B1 (de) 2008-05-21
DE69717661T2 (de) 2003-09-25
CA2271388C (en) 2007-11-06
JP2001502299A (ja) 2001-02-20
EP0938298B1 (de) 2002-12-04
EP0938298A1 (de) 1999-09-01
CN1138533C (zh) 2004-02-18
AU4215497A (en) 1998-04-02
AU728581B2 (en) 2001-01-11
EP1254657A2 (de) 2002-11-06
DE69738719D1 (de) 2008-07-03
ATE228824T1 (de) 2002-12-15

Similar Documents

Publication Publication Date Title
ATE395904T1 (de) Liposome
WO1997049423A3 (en) Liposomal influenza vaccine composition and method
DE69536091D1 (de) Immunisierung durch Impfung von DNS Transkriptionseinheit
ZA9811948B (en) Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom.
WO1999041368A3 (en) Optimization of immunomodulatory properties of genetic vaccines
NO20001768D0 (no) Viruskapsomervaksine, fremgangsmåte til fremstilling samt anvendelse derav
AU1013601A (en) Method of inducing and/or enhancing an immune response to tumor antigens
FI971530A0 (fi) Lipaasi, sitä tuottava mikro-organismi, menetelmä lipaasin valmistamiseksi ja sen käyttö
HK1025906A1 (en) Liposome-entrapped polynucleotide composition and method
EP0904393A4 (de) Parapockenvirus-vektoren
BR9506885A (pt) Vacinas contendo vesículas de lipidio paucilamelares como adjuvantes imunológicos
EP0934083A4 (de) Verbesserte impfstoffe
WO1999025861A3 (fr) Vecteurs adenoviraux et methode de reduction des evenements de recombinaison homologue
AU3926097A (en) Improved inactivated vaccines
AU1991097A (en) Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-linked treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases
WO2003035032A3 (en) New non-phospholipid lipid vesicles (nplv) and their use in cosmetic, therapeutic and prophylactic applications
WO1997011669A3 (en) MHC-class II restricted melanoma antigens and their use in therapeutic methods
AU1681095A (en) Hydrophilic signal oligopeptides and methods of therapeutic use
AU4627897A (en) Bordetella strain expressing the hybrid FHA, liposomes and vaccines
WO1993017115A3 (en) Dysentery vaccine stimulating an immune response against shigatoxin, plasmids and host strains for it
WO1999016466A3 (en) Vaccine compositions and methods of enhancing vaccine efficacy
AU3956195A (en) Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same
WO2000016746A3 (en) Immunogenic liposome compositions
PT729509E (pt) Vacina contra papeira contendo uma estirpe do virus jerryl-lynn
MX9603547A (es) Vacunas que contienen vesiculas de lipido paucilamelar como adyuvantes inmunologicos.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties